drugset
drugset / Trial / NCT05772377

Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer

NCT05772377 ↗

Phase 2 Unknown 36 enrolled The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment

Summary

To observe the efficacy and safety of hydrochloride anlotinib combined with concurrent radiochemotherapy for patients with FIGO stage IB3 and IIA2-IVA cervical cancer.

Timeline

Start
2023-07-01
Primary completion
2024-06-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — —
Subject Catequentinib Small molecule 8 mg Oral
Subject Catequentinib Small molecule 10 mg Oral
Subject Cisplatin Other / unclassified 30 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 35 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous

Indications

No indication recorded.